Page last updated: 2024-12-05

methylguanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methylguanidine (MG) is a simple organic compound with the formula CH6N3. It is a colorless solid that is soluble in water. MG is a natural product found in living organisms, and is also synthesized industrially. MG is a potent inhibitor of various enzymes, including acetylcholinesterase and nitric oxide synthase. It has been shown to have a variety of biological effects, including anti-inflammatory, analgesic, and neuroprotective activities. It is a known neurotoxin and is linked to the onset of neurodegenerative diseases. MG is also implicated in the pathogenesis of several diseases, including diabetes, cancer, and Alzheimer's disease. As a result, it is an important area of research to better understand its physiological role and its impact on health.'

Methylguanidine: A product of putrefaction. Poisonous. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylguanidine : A guanidine in which one of the amino hydrogens of guanidine itself is substituted by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10111
CHEBI ID16628
MeSH IDM0013642

Synonyms (32)

Synonym
monomethyl guanidin
mgx ,
CHEBI:16628
n-methylguanidine
monomethylguanidine
1-methylguanidine
methylguanidin
n1-methylguanidine
guanidine, methyl-
einecs 207-438-3
monomethyl guanidin [german]
methylguanidin [german]
471-29-4
methylguanidine
C02294
2-methylguanidine
AKOS005720837
BBL011356
FT-0672364
STL146448
unii-5l0h5q9vag
5l0h5q9vag ,
FT-0608084
methylguanidine [mi]
methyl- guanidine
n-methyl guanidine
DTXSID4020872
methylguandine
2-methylguanidin
r016192 ,
Q27102005
EN300-21662

Research Excerpts

Overview

Methylguanidine (MG) is a known nephrotoxin and neurotoxin. An intracisternal injection of MG can induce convulsions in experimental animals.

ExcerptReferenceRelevance
"Methylguanidine (MG) is a known nephrotoxin and neurotoxin, and an intracisternal injection of MG can induce convulsions in experimental animals. "( The Anticonvulsant Zonisamide Inhibits Hydroxyl Radical Generated from Methylguanidine.
Masumizu, T; Mori, A; Noda, Y, 2016
)
2.11
"1. Methylguanidine is a suspected uraemic toxin that accumulates in renal failure. "( Production of methylguanidine in dogs with acute and chronic renal failure.
Boppana, VK; Brooks, DP; Griffin, HE; Kinter, LB; Mallon, FM; Rhodes, GR; Woodward, P, 1989
)
1.26

Effects

ExcerptReferenceRelevance
"Methylguanidine has been examined by the new single method of ion pair extraction and has been found in higher concentration in uremic plasma than in normal, but in lower concentration than previously described with less selective method and used in experimental animal intoxication."( Chemical analytic approaches to the definition of uremic toxins.
Bergstrom, J; Furst, P; Gordon, A; Zimmermann, L,
)
0.85

Toxicity

ExcerptReferenceRelevance
" The toxic effects are discussed on the basis of these results."( Comparison of toxic effects of methylguanidine, guanidinosuccinic acid and creatinine in rats with adenine-induced chronic renal failure.
Mo, ZL; Oura, H; Yokozawa, T, 1989
)
0.56
" The present study was designed to explore the toxic effect of MG on renal proximal tubular cells as well as the protective effect of antioxidants PGE1 and probucol against MG-induced apoptosis in renal proximal tubular cells."( Methylguanidine cytotoxicity on HK-2 cells and protective effect of antioxidants against MG-induced apoptosis in renal proximal tubular cells in vitro.
Jiang, YS; Ling, GH; Wang, F; Yang, B; Yao, C, 2010
)
1.8

Dosage Studied

ExcerptRelevanceReference
" Adverse reactions led to drug discontinuation in six and dosage reduction in eight patients."( Meobentine sulfate: antiarrhythmic and electrophysiologic effects assessed by programmed electrical stimulation and ambulatory monitoring in patients with complex ventricular tachyarrhythmia. Report of a multicenter evaluation.
Akhtar, M; Anderson, JL; Jueng, P; Long, RA; Platia, EV; Reid, PR; Ruskin, JN; Schaal, SF; Wenger, TL, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
EC 1.14.13.39 (nitric oxide synthase) inhibitorAn EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of nitric oxide synthase (EC 1.14.13.39).
uremic toxinA toxin that accumulates in patients with chronic kidney disease.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (268)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990109 (40.67)18.7374
1990's85 (31.72)18.2507
2000's37 (13.81)29.6817
2010's35 (13.06)24.3611
2020's2 (0.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.25 (24.57)
Research Supply Index5.70 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index47.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (2.76%)5.53%
Reviews11 (3.79%)6.00%
Case Studies3 (1.03%)4.05%
Observational0 (0.00%)0.25%
Other268 (92.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]